Cargando…

Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients

PD-1 pathway blockade has been shown to promote proatherogenic T-cell responses and destabilization of atherosclerotic plaques. Moreover, preclinical evidence suggests a potential synergy of antiplatelet drugs with immune checkpoint inhibitors (ICIs). We conducted an analysis within a prospective ob...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nichetti, Federico, Ligorio, Francesca, Zattarin, Emma, Signorelli, Diego, Prelaj, Arsela, Proto, Claudia, Galli, Giulia, Marra, Antonio, Apollonio, Giulia, Porcu, Luca, de Braud, Filippo, Lo Russo, Giuseppe, Ferrara, Roberto, Garassino, Marina Chiara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016680/ https://www.ncbi.nlm.nih.gov/pubmed/31881699 http://dx.doi.org/10.3390/cancers12010067

Ejemplares similares

Risk assessment of thromboembolic events in hospitalized cancer patients
por: Nichetti, Federico, et al.
Publicado: (2021)

Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations
por: Ferrara, Roberto, et al.
Publicado: (2021)

Evaluation of Drug—Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors
por: Occhipinti, Mario, et al.
Publicado: (2021)

SMO mutations confer poor prognosis in malignant pleural mesothelioma
por: Signorelli, Diego, et al.
Publicado: (2020)

Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression
por: Prelaj, Arsela, et al.
Publicado: (2021)

Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC
por: Signorelli, Diego, et al.
Publicado: (2022)

Machine Learning Using Real-World and Translational Data to Improve Treatment Selection for NSCLC Patients Treated with Immunotherapy
por: Prelaj, Arsela, et al.
Publicado: (2022)

Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system
por: Prelaj, Arsela, et al.
Publicado: (2020)

EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort
por: Prelaj, Arsela, et al.
Publicado: (2019)

Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications
por: Vernieri, Claudio, et al.
Publicado: (2020)

Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors
por: Fucà, Giovanni, et al.
Publicado: (2019)

Case Report: Prolonged clinical benefit with sequential trastuzumab-containing treatments in a patient with advanced extramammary Paget disease of the groin
por: Zattarin, Emma, et al.
Publicado: (2022)

Fasting-mimicking diet plus chemotherapy in breast cancer treatment
por: Vernieri, Claudio, et al.
Publicado: (2020)

Concomitant EML4-ALK rearrangement and EGFR mutation in non-small cell lung cancer patients: a literature review of 100 cases
por: Lo Russo, Giuseppe, et al.
Publicado: (2017)

Cost-effectiveness analysis of two thromboprophylactic strategies following major surgery
por: Ebm, C, et al.
Publicado: (2012)

IMPACT OF THROMBOPROPHYLACTIC STRATEGY ON BLEEDING RISK AMONG IN- AND OUTPATIENTS WITH COVID-19
por: Svet, Mark, et al.
Publicado: (2021)

MicroRNAs for the Diagnosis and Management of Malignant Pleural Mesothelioma: A Literature Review
por: Lo Russo, Giuseppe, et al.
Publicado: (2018)

Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patients
por: Prelaj, Arsela, et al.
Publicado: (2023)

Prognostic impact of body mass index (BMI) in HER2+ breast cancer treated with anti-HER2 therapies: from preclinical rationale to clinical implications
por: Ligorio, Francesca, et al.
Publicado: (2022)

Neuraxial and peripheral nerve blocks in patients taking anticoagulant or thromboprophylactic drugs: challenges and solutions
por: Li, Jinlei, et al.
Publicado: (2015)

Antitumor activity and efficacy of shorter versus longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II–III HER2-negative breast cancer: a 10-year, retrospective analysis
por: Lobefaro, Riccardo, et al.
Publicado: (2020)

The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)—Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab
por: Ligorio, Francesca, et al.
Publicado: (2021)

Thromboprophylactic Efficacy and Safety of Anticoagulants After Arthroscopic Knee Surgery: A Systematic Review and Meta-Analysis
por: Yu, Yang, et al.
Publicado: (2019)

Oral Capecitabine-Vinorelbine Is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer
por: Vernieri, Claudio, et al.
Publicado: (2020)

PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers
por: Lo Russo, G., et al.
Publicado: (2022)

Real-World Management of Pharmacological Thromboprophylactic Strategies for COVID-19 Patients in Japan: From the CLOT-COVID Study
por: Hayashi, Hiroya, et al.
Publicado: (2022)

Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients
por: Ligorio, Francesca, et al.
Publicado: (2021)

Case Report: Exceptional Response to Poziotinib in Patient with Metastatic Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutation
por: Prelaj, Arsela, et al.
Publicado: (2022)

Radium-223 in patients with metastatic castration-resistant prostate cancer: Efficacy and safety in clinical practice
por: Prelaj, Arsela, et al.
Publicado: (2019)

PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis
por: Lo Russo, Giuseppe, et al.
Publicado: (2023)

Beyond LKB1 Mutations in Non-Small Cell Lung Cancer: Defining LKB1less Phenotype to Optimize Patient Selection and Treatment
por: Borzi, Cristina, et al.
Publicado: (2020)

Non-conventional fotemustine schedule as second-line treatment in recurrent malignant gliomas: Survival across disease and treatment subgroup analysis and review of the literature
por: Prelaj, Arsela, et al.
Publicado: (2019)

The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis
por: Provenzano, Leonardo, et al.
Publicado: (2023)

Impact of dexamethasone-sparing regimens on delayed nausea caused by moderately or highly emetogenic chemotherapy: a meta-analysis of randomised evidence
por: Celio, Luigi, et al.
Publicado: (2019)

Real-World Comparative Effectiveness and Cost Comparison of Thromboprophylactic Use of Enoxaparin versus Unfractionated Heparin in 376,858 Medically Ill Hospitalized US Patients
por: Veeranki, S. Phani, et al.
Publicado: (2020)

LKB1 mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial
por: Vernieri, Claudio, et al.
Publicado: (2020)

Multimodal treatment for local recurrent malignant gliomas: Resurgery and/or reirradiation followed by chemotherapy
por: Prelaj, Arsela, et al.
Publicado: (2019)

Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications
por: Zattarin, Emma, et al.
Publicado: (2020)

Successful treatment of triple EGFR mutation T785A/L861Q/H297_E298 with afatinib
por: Longo, Vito, et al.
Publicado: (2021)

Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial
por: Cools, Frank, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s5i449en64h6d4efvva2tn981c